

Filed: January 9, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.

Petitioners,

v.

ASTRAZENECA AB.

Patent Owner.

---

Case No. IPR2016-01316 (6,774,122)

Case No. IPR2016-01324 (7,456,160)

Case No. IPR2016-01325 (8,329,680)

Case No. IPR2016-01326 (8,466,139)<sup>1</sup>

---

**JOINT REQUEST THAT SETTLEMENT AGREEMENT BE TREATED AS  
BUSINESS CONFIDENTIAL INFORMATION AND KEPT SEPARATE  
UNDER 35 U.S.C. § 317(b) AND 37 C.F.R. § 42.74(c)**

---

<sup>1</sup> A word-for-word identical Request is being filed in each proceeding.

Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c), Petitioner and Patent Owner jointly request that the settlement agreement filed concurrently herewith and referenced in the concurrently-filed Joint Motion to Terminate the Proceedings Under 35 U.S.C. § 317(a) be treated as business confidential information and kept separate from the files of the involved patent and IPR2016-01316, IPR2016-01324, IPR2016-01325, and IPR2016-01326 and only made available to Federal Government agencies upon written request or to any other person upon written request and a showing of good cause.

Dated: January 9, 2017

/Brandon M. White/

Brandon M. White

Reg. No. 52,354

Perkins Coie LLP

700 13th St., NW, Suite 600

Washington, D.C. 20005

Telephone: (202) 654-6206

E-mail: [bmwhite@perkinscoie.com](mailto:bmwhite@perkinscoie.com)

*Attorney for Mylan Pharmaceuticals Inc.*

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that the foregoing *Joint Request That Settlement Agreement Be Treated As Business Confidential Information and Kept Separate Under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c)* was served electronically via email as follows:

Filko Prugo  
fprugo@omm.com

Marc Pensabene  
mpensabene@omm.com

Caitlin Hogan  
chogan@omm.com

John Murray  
kmurray2@omm.com

Dated: January 9, 2017

/Brandon M. White/  
Brandon M. White

*Attorney for Mylan Pharmaceuticals Inc.*